News Briefing channel feed

Nor­we­gian biotech to en­act lay­offs; Uni­ty halves its pub­lic of­fer­ing

3 years ago

Astel­las' hot flash­es drug will get speedy re­view at FDA; US opts out of Val­ne­va vac­cine

3 years ago

TYK2 heats up with Ven­tyx eye­ing mid-stage tri­als; Nex­Im­mune cites com­pe­ti­tion in pipeline cull

3 years ago

An an­tibi­otics play­er ax­es staff in wake of PhI­II fail; Hori­zon to fund an­ti­body de­vel­op­ment, with op­tion to buy

3 years ago

Check­point ends tri­al due to Russ­ian in­va­sion; Terns lines up more cash for NASH

3 years ago

Graphite Bio be­gins SCD cell ther­a­py tri­al; Syn­thet­ic Bi­o­log­ic­s' fu­ture rests on VCN ac­qui­si­tion

3 years ago

Pen­ny stock biotech miss­es on its sole clin­i­cal tri­al; Cal­adrius teams up with Roche for pan­cre­at­ic can­cer col­lab­o­ra­tion

3 years ago

BioCryst re­sumes en­roll­ment for im­mune dis­eases drug; Ea­gle buys stake in res­pi­ra­to­ry dis­ease biotech

3 years ago

Clo­vis says it needs mon­ey af­ter re­verse split vot­ed down; Cin­Cor touts PhII da­ta for hy­per­ten­sion drug

3 years ago

Gen­mab and BioN­Tech to col­lab­o­rate on new can­cer can­di­date; Small Aus­tralian biotech sees hope in brain metas­tases tri­al

3 years ago

FDA de­lays PDU­FA date for Lib­tayo lung can­cer com­bo; Swedish biotech hit flunks PhI­II for chemo-en­hanc­ing drug

3 years ago

Af­ter a bust with knee pain drug and 3 Covid-19 flops, Am­pio lays off staff; An­ti­body start­up nabs sec­ond deal in two weeks

3 years ago
R&D

FDA green­lights Mar­ius' oral hy­pog­o­nadism pill; VBL Ther­a­peu­tics makes cuts to its work­force

3 years ago

Pri­or­i­ty re­view for Gami­da's cell ther­a­py; PhI­II shut­tered at Akari; Im­mutep drops da­ta on LAG3 study

3 years ago

Io­n­is, Cy­cle­ri­on tout pos­i­tive da­ta read­outs; MA­IA prices first biotech IPO in over two months

3 years ago

FDA ac­cepts Lex­i­con's heart fail­ure re­sub­mis­sion; Bris­tol My­ers buys out mava­camten roy­al­ties

3 years ago

Galectin gets $60M cred­it line from bil­lion­aire chair; In­flam­ma­to­ry dis­ease biotech reach­es SPAC deal

3 years ago

No­var­tis gener­ics arm files for MS biosim­i­lar, chal­leng­ing Bio­gen; Pluris­tem short­ens name

3 years ago

Ver­tex wins 'break­through' nod for non-opi­oid pain drug; Af­ter US with­draw­al, EMA re­stricts Clo­vis' Rubra­ca

3 years ago

F-star lines up Take­da pact weeks af­ter M&A ex­it; En route to Eu­rope de­ci­sion, Gen­Sight touts 5-year da­ta

3 years ago

Apel­lis nabs pri­or­i­ty re­view for ge­o­graph­ic at­ro­phy pitch; Bris­tol My­ers ex­tends of­fer time­line on Turn­ing Point buy­out

3 years ago

An old epilep­sy med gets oral liq­uid for­mu­la­tion nod; PMV pairs up AS­CO stand­out with Keytru­da

3 years ago

Vir CSO de­part­ing next month to be Al­tos CMO; Bob Dug­gan’s Sum­mit Ther­a­peu­tics and the FDA try to make head­way

3 years ago

Mubadala Cap­i­tal-backed on­col­o­gy biotech adds more cash to Se­ries A; Opti­nose shares pooled da­ta on nasal spray

3 years ago
First page Previous page 21222324252627 Next page Last page
A service from the Financial Times